Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Stockholders' Equity

v3.7.0.1
Consolidated Statement of Stockholders' Equity - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-In Capital [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, shares at Dec. 31, 2014 305,000 11,885,414        
Beginning balance, value at Dec. 31, 2014 $ 31 $ 118,854 $ 5,241,418 $ 9,562,517 $ 121,004 $ 15,043,824
Retrospective application of Reverse Stock Split, shares   (11,489,233)        
Retrospective application of Reverse Stock Split, value   $ (114,892) 114,892      
Common stock issued for services, shares   10,583        
Common stock issued for services, value   $ 106 2,904,894     2,905,000
Exercise of stock options, shares issued   13,655        
Exercise of stock options, value   $ 137 2,499,863     2,500,000
Preferred stock converted to common stock, shares converted (255,000)          
Preferred stock converted to common stock, value converted $ (26)   (4)      
Preferred stock converted to common stock, shares issued   2,959        
Preferred stock converted to common stock, value issued   $ 30        
Stock-based compensation     722,829     722,829
Adjust noncontrolling interest in Biohealth         (121,004) (121,004)
Ending balance, shares at Nov. 02, 2015 50,000 423,378        
Ending balance, value at Nov. 02, 2015 $ 5 $ 4,234 11,483,893 9,562,517 0 21,050,649
Beginning balance, shares at Dec. 31, 2014 305,000 11,885,414        
Beginning balance, value at Dec. 31, 2014 $ 31 $ 118,854 5,241,418 9,562,517 121,004 15,043,824
Dividends on Series B preferred stock           (1,627,188)
Net loss           (35,962,506)
Ending balance, shares at Dec. 31, 2015 59,000 488,398        
Ending balance, value at Dec. 31, 2015 $ 590 $ 4,884 26,827,904 (28,027,177) 0 (1,193,799)
Beginning balance, shares at Nov. 02, 2015 50,000 423,378        
Beginning balance, value at Nov. 02, 2015 $ 5 $ 4,234 11,483,893 9,562,517 0 21,050,649
Cancellation of Medytox shares, shares cancelled (50,000)          
Cancellation of Medytox shares, value $ (5)   5      
Issuance of Rennova shares, shares issued 50,000          
Issuance of Rennova shares, value $ 500   (500)      
Common stock issued for cash, shares 9,000 21,506        
Common stock issued for cash, value $ 90 $ 215 8,843,032     8,843,337
Shares issued with merger, shares issued   43,514        
Shares issued with merger, value   $ 435 13,520,829     13,521,264
Allocation of offering proceeds to derivative liabilities     (7,019,355)     (7,019,355)
Dividends on Series B preferred stock       (1,627,188)   (1,627,188)
Net loss       (35,962,506)   (35,962,506)
Ending balance, shares at Dec. 31, 2015 59,000 488,398        
Ending balance, value at Dec. 31, 2015 $ 590 $ 4,884 26,827,904 (28,027,177) $ 0 (1,193,799)
Common stock issued for cash, shares 12,350          
Common stock issued for cash, value $ 124   11,819,141     11,819,265
Common stock issued for services, shares   8,777        
Common stock issued for services, value   $ 88 73,247     73,335
Preferred stock converted to common stock, shares converted (12,823)          
Preferred stock converted to common stock, value converted $ (130)          
Preferred stock converted to common stock, shares issued   1,447,593        
Preferred stock converted to common stock, value issued   $ 14,475 (14,345)      
Cashless exericse of warrants, shares issued   1,627        
Cashless exericse of warrants, value   $ 16 (16)      
Shares issued in adjustment of prior conversion of preferred stock, shares   1,687        
Shares issued in adjustment of prior conversion of preferred stock, value   $ 17 (17)      
Stock-based compensation     858,868     858,868
Common shares cancelled, shares   (1,366)        
Common shares cancelled, value   $ (14) 14      
Exchange of Series C Preferred Stock and warrants for Series G Preferred Stock and warrants, shares 5,053          
Exchange of Series C Preferred Stock and warrants for Series G Preferred Stock and warrants, value $ 51   (51)      
Common stock and warrants issued for cash, shares   637,167        
Common stock and warrants issued for cash, value   $ 6,372 7,514,664     7,521,036
Conversion of related party liabilities into common stock, shares   192,223        
Conversion of related party liabilities into common stock, value   $ 1,922 2,229,907     2,231,829
Common stock granted to employees, shares   24,271        
Common stock granted to employees, value   $ 243 248,376     248,619
Cancellation of Series E Preferred Stock, shares (45,000)          
Cancellation of Series E Preferred Stock, value $ (450)   450      
Cancellation of warrants not qualifying for equity treatment, value     1,854,546     1,854,546
Reclassification of derivative liability     2,265,742     2,265,742
Warrants and beneficial conversion features related to the issuance of convertible notes     394,500     394,500
Redemption of Series G Preferred Stock, shares redeemed (8,346)          
Redemption of Series G Preferred Stock, value $ (83)   (8,346,067)     (8,346,150)
Dividends on Series B preferred stock           0
Net loss       (32,613,687)   (32,613,687)
Ending balance, shares at Dec. 31, 2016 10,234 2,800,377        
Ending balance, value at Dec. 31, 2016 $ 102 $ 28,004 $ 45,726,862 $ (60,640,864)   $ (14,885,896)